65,437 trials
Osteoarthritis
Primary: Percentage of Subjects Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Score (ITT) >=40% and 15 mm From Baseline Through 12 Weeks…
Human Papillomavirus Infection
Primary: Female Sexual Function Index (FSFI) Score — 0.8; 1.2; 0.9; 0.7 score on a scale
Prostate Cancer
Primary: Median Time to Progression (TTP) — 5.1; 3.0 months — p=< 0.005
Migraine
Primary: Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan — 362; 426 nanograms per milliliter (ng/mL)
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Weighted Mean Pulse Rate Over (0-4 Hours) at Day 28. — -3.8; -4.8 Beat per minute (bpm)
Lymphoma
Primary: Overall Response Rate (ORR) — 67.7; 29.0; 3.3 Percentage of Participants
Communication
Primary: Rate of Medical Errors — 41.2; 35.8; 20.0; 22.0 Medical errors per 1000 patient-days
Stroke
Primary: Upper Extremity Fugl-Meyer Score — 88; 43 Participants — p=0.76
Hereditary Pulmonary Alveolar Proteinosis
Primary: Change in Time (Minutes) to Discontinuation of Exercise During a Standardized Treadmill Exercise Test — 17; 33 Percent Change
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Primary: Subjects Included in the Composite Endpoint of CV Death, Hospitalization Due to Heart Failure or Urgent Visit Due to Heart Failure. — 386; 502 Participants — p=<0.0001
DS Stage I Plasma Cell Myeloma · DS Stage II Plasma Cell Myeloma · DS Stage III Plasma Cell Myeloma
Primary: Determine Maximum Tolerated Dose by the Number of Patients With a DLT Per Dose Level — 1; 0; 0; 0 Participants
Chest Pain
Primary: Percent of Subjects Receiving 4 Cycles of RIC Without Interruption — 80 percentage of participants
Attention-Deficit/Hyperactivity Disorder
Primary: Scores of Teacher and Parent Rated Inattentive Symptoms — 2.00; 2.08; 1.51; 1.60 units on a scale
Cerebral Palsy · Developmental Delay · Infant Development
Primary: Bayley Scales of Infant Development III — 35.9; 33.6; 31.7; 29.4 score on a scale — p=<0.05
Human Papilloma Virus
Primary: Overall HPV Vaccine Completion Rates — 1961; 1083 Participants